Splenic Marginal Zone Lymphoma · line 2 · R-Bendamustine for relapsed marginal zone lymphoma (post-rituximab failure)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-R-BENDAMUSTINE-RELAPSED-MZL`

ID	`IND-SMZL-2L-BR`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-SPLENIC-MZL`
Sources	`SRC-BSH-MZL-2024` `SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

Standard-track 2L SMZL after rituximab monotherapy failure. Re-uses REG-R-BENDAMUSTINE-RELAPSED-MZL. Alternative: ibrutinib monotherapy (separate Indication when access available).

Used By

Algorithms

ALGO-SMZL-2L - ALGO-SMZL-2L